Volume 69 Numbers 1 & 2 January/March 2002	back to contents

Rofecoxib-Associated Upper Gastrointestinal Bleed: A Case Report	105-106
Gordon M. Freedman, M.D.1, Joel M. Kreitzer, M.D.2, and Ruchi Badola, M.D.3

¹Clinical Assistant Professor of Anesthesiology, ²Clinical Associate Professor of Anesthesiology, and ³Pain Management Fellow, Mount Sinai School of Medicine, New York, NY.

Address correspondence to Gordon Freedman, M.D., Associate Director, Pain Management Service, Box 1192, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029.

ABSTRACT

To our knowledge, this is the first clinical report of a rofecoxib-associated upper gastrointestinal hemorrhage. We urge caution in prescribing rofecoxib to patients with risk factors for peptic ulcer disease and recommend limiting the dose to 25 mg per day for these patients.

KEYWORDS

Rofecoxib, cyclo-oxygenase-2 inhibitor, nonsteroidal anti-inflammatory drug, peptic ulceration, upper gastrointestinal bleed.

MSSM Home

Back Issues | Indexes | Search | Journal Home